Background. Troponin increment is a highly sensitive and specific marker of myocardial necrosis. The reason of high troponin levels in acute stroke is not clear. The aim of this study was to identify the relationships between cardiac troponin-I (cTnI) level and stroke. Methods. This study recruited 868 patients who were admitted to Istanbul Medeniyet University due to acute ischemic stroke, and the diagnosis was confirmed by diffusion magnetic resonance imaging. The patients with the causes increasing troponin level were excluded from the study. A total of 239 patients were finally included in the study. Clinics were evaluated by the modified Rankin Scale (mRS) and the National Institutes of Health Stroke Scale (NIHSS). Results. Serum level of troponin was higher in ischemic stroke patients with anterior circulation involvement in comparison to posterior involvement or hemorrhagic stroke (P < 0.05). Higher troponin levels related to increased stroke scale scores at discharge in ischemic stroke (P < 0.05). The level of cTnI was correlated with stroke scale scores at both admission and discharge in posterior stroke patients (P < 0.01). Conclusion. cTnI is a highly specific and sensitive marker of myocardial damage, and its elevation was associated with more severe neurological deficits in acute ischemic stroke.

Objective: Decreased serum uric acid has been associated with neurodegenerative diseases such as Parkinson's disease (PD) in the elderly. Several studies suggest that there may be a link between PD and Essential tremor (ET) which is thought to be a neurodegenerative disease. Serum uric acid level (UA) and its relationship with prognosis in ET patients have not been addressed. Study Population: The current study was conducted in the outpatient neurology unit of Istanbul Medeniyet University Medical Faculty Göztepe Teaching Hospital between May 2011 and Sep 2013. Methods: Subjects with ET were evaluated. We collected serum samples to determine biochemical indicators including UA, glucose, blood lipids, liver function, and renal function. All the patients with vascular risk factors, dementia, depression or other neurodegenerative disorders were excluded, as were the subjects on uric acid-lowering therapy or with serious illnesses such as severe anemia, chronic renal failure, hepatic disease or active or ongoing cardiovascular or cerebral vascular disease. One hundred and sixteen subjects (52 isolated ET patients and 64

No abstract

No abstract

No abstract